Global Market for Research Tools Diagnostics and Drug Discovery

March 15, 2013

Wellesley, Mass. – Biomarker development and current epigenetic diagnostics market trends in the specific segment for histone methyltransferase (HMT) diagnostics is estimated at around $1 million per year.  Product development and progress is definitely expected in the next five years, possibly with more companies focusing on different HMTs as diagnostics targets. It is estimated that this specific niche may grow to at least $5 million by 2018, with new pipelines and projects in development, including prognostics and companion diagnostics tools.

The main driver in this sector is its true commercial potential: Based on current diagnostics market analysis, especially in oncology, tests using HMTs as a target may bring substantial revenues to companies.  Many studies show that HMTs play essential roles in tumor development and cancer progression; therefore, substantial progress in product development is expected in the next five years. 

The global market for HMTs is more than $100 million. The research tools and assay development sector is the most stable segment in this market, showing slow yet consistent growth. There is still a big necessity for the development of efficient and reliable assays and tools for HMT research.

The drug discovery niche consists of a small number of representative companies with definite leaders on the market.  Recent drug development in Epizyme’s pipeline and the introduction of new Dot1L inhibitor into clinical trials for the first time bring a lot of attention to HMT research and consequently helps to grow this market further. More collaboration and partnerships are expected in the next couple of years.

A diagnostics segment is still in a very premature state. Nevertheless, the biomarker industry sees enormous commercial potential in HMT research, which was shown to be tightly correlated with cancer development. New diagnostics products using HMTs as biomarkers are expected. Recent companion diagnostics developments by Epizyme, Eisai, and Roche are examples of such progress.  The HMT market is considered a new emerging pharmaceutical and diagnostics space with big commercial potential.

Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery (PHM128A) focuses on recent technologies, tools and applications, products, deals between different companies, major participants, and new trends and development during the last few years. It will forecast future situations and address major drawbacks of HMTs and possible solutions for these obstacles. 

This report is intended for business development professionals, entrepreneurs, and other investors who need to fully understand and properly evaluate each segment in the market for histone methyltransferases research and development. It provides insights into the market position of major companies, and shows new opportunities otherwise overlooked or less known to the business community.

To Contact us, click here  

Histone Methyltransferases: Global Markets for Research Tools, Diagnostics and Drug Discovery( PHM128A )
Publish Date: Mar 2013    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.